Pacira Biosciences Inc
pacira.comWhat Do They Do?
Sells non-opioid pain treatments, including injectable medicines for postsurgical and knee pain and a handheld nerve-pain device, to healthcare providers.
10-K for FY2025, filed Feb 26, 2026Our mission is to deliver innovative, non-opioid pain therapies to transform the lives of patients. We have three commercialized non-opioid…View ↗
EXPAREL was approved by the FDA in October 2011 and was commercially launched in the U.S. in April 2012. EXPAREL is a long-acting…View ↗
ZILRETTA is the first and only extended-release, single-shot corticosteroid IA injection therapy for OA knee pain. ZILRETTA employs a…View ↗
The iovera° system is a non-opioid handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature to targeted…View ↗
We have built our sales and marketing organization to commercialize our products. Our primary target audiences are healthcare practitioners…View ↗
How Do They Make Money?
Pacira sells EXPAREL through wholesaler orders tied to end-user demand and sells ZILRETTA mainly through specialty distributors and pharmacies; payment terms generally run zero to four months from the transaction.
10-K for FY2025, filed Feb 26, 2026
$726.4M
-
10-K for FY2025, filed Feb 26, 2026
$726.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product sales
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
100%
FY2022: 100%
|
Net product sales, FY2025
$722.9M Sources
|
Sold outright |
|
Royalty revenue
Licensed
|
0.5%
FY2022: 0.4%
|
Royalty revenue, FY2025
$3.6M Sources
|
Licensed |
Who Are Their Customers?
Healthcare providers use Pacira’s products for postsurgical and knee pain. EXPAREL orders run through wholesalers and ship directly to hospitals, surgery centers and provider offices; ZILRETTA is sold mainly through specialty distributors and pharmacies.
10-K for FY2025, filed Feb 26, 2026Our mission is to deliver innovative, non-opioid pain therapies to transform the lives of patients. We have three commercialized non-opioid…View ↗
The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product…View ↗
We have built our sales and marketing organization to commercialize our products. Our primary target audiences are healthcare practitioners…View ↗
10-K for FY2025, filed Feb 26, 2026
We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2025: McKesson Drug…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 1 cent of every revenue dollar as net income in FY2025 and turned 19 cents into free cash flow.
10-K for FY2025, filed Feb 26, 2026
$19.2MView ↗
10-K for FY2025, filed Feb 26, 2026
$7MView ↗
10-K for FY2025, filed Feb 26, 2026
$136.7MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 4, 2026
$4.7MView ↗
- ▲ Now profitable
- vs −$4.8M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 4, 2026
Open tableView ↗
-
Jun 30, 2026
Agreed to sell iovera business to Zimmer Biomet
The deal includes $70 million upfront and up to $70 million in revenue-based milestone payments; closing is expected in the third quarter of 2026.
Sources
8-K, filed Jun 30, 2026
On June 28, 2026, Pacira BioSciences, Inc. (the “Company”) and Pacira CryoTech, Inc., the Company’s wholly owned subsidiary (the…View ↗
Growing. Revenue grew 34% in 4 years, from $541.5M in FY2021 to $726.4M in FY2025, about 8% a year.
Broader EXPAREL use
EXPAREL’s approved uses have expanded from infiltration and an interscalene block to also include adductor canal and sciatic nerve blocks, extending its postsurgical pain offering for additional surgeries.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026EXPAREL was approved by the FDA in October 2011 and was commercially launched in the U.S. in April 2012. In the U.S., EXPAREL is currently…View ↗
EXPAREL was approved by the FDA in October 2011 and was commercially launched in the U.S. in April 2012. EXPAREL is a long-acting…View ↗
Who Do They Compete With?
Competes with Avanos Medical
10-K for FY2025, filed Feb 26, 2026Besides pharmaceutical products for pain management, iovera° competes with medical devices that ablate or degenerate peripheral nerves to…View ↗
Loading...
